The CSA DESIGN OH AMR, in collaboration with JPIAMR and other stakeholders is leading the development of the One Health AMR Partnership. The main goal is to contribute to achieving the objectives of the European One Health Action Plan against AMR and the WHO Global Action Plan on AMR, both aimed at reducing the threat of antimicrobial resistance (AMR). The first call and launch of other activities of this joint research programme between the European Commission and Member States are planned to take place in 2025.
In the research framework of Horizon Europe, the European Commission, in collaboration with the member states, has identified 49 new candidate European Partnerships of which, one of them is the “One Health AMR Partnership”. The One Health AMR (OH AMR) will be a partnership co-funded by EU countries and the European Commission, with research funders and ministries at the core of the consortium. A Strategic Research and Innovation Agenda (SRIA) will be developed and implemented through joint calls and additional activities. The main goal is to contribute to achieving the objectives of the European One Health Action Plan against AMR and the WHO Global Action Plan on AMR, both aimed at reducing the threat of antimicrobial resistance (AMR).
The OH AMR Partnership aims to coordinate and align AMR activities and funding between countries as well as with the Commission. It will also facilitate national coherence between different services and ministries with responsibility for the various aspects of AMR (e.g. human health, agriculture, environment, industry, finances).
The core group of formal members and signatories will comprise relevant ministries and funding agencies from the participating countries.
- Countries: EU Member States and Associated Countries funding agencies
- European Commission lead: DG Research and Innovation – Combating Diseases
- Lead of the preparation of the partnership: The CSA DESIGN OH AMR in collaboration with JPIAMR and other stakeholders.
- Novel solutions to prevent and treat infectious diseases affected by AMR, improved diagnosis and control of the spread of resistant microorganisms, testing and validation of such solutions and facilitating their uptake or implementation.
- Decreased burden of infectious diseases, notably due antimicrobial resistant pathogens and progress towards Sustainable Development Goal No. 3 ‘Ensure healthy lives and promote well-being for all at all ages’.
- Closed knowledge gaps on AMR (including those identified in the European One Health Action Plan against AMR and the EU Strategic Approach to Pharmaceuticals in the Environment), support provided to regulatory science and inform policymaking.
The Strategic Research and Innovation Agenda, SRIA
The first draft of the European Partnership OH AMR Strategic Research and Innovation Agenda, SRIA has been developed through a number of consultations and was published on 22 May 2023.
An important element of the SRIA are the Research and Innovation (R&I) Objectives. To get a full understanding of the R&I objectives, please consult the long version where each R&I objective is described in detail.
The Research and Innovation Objectives are structured around five thematic areas and includes several cross-cutting themes.
To read the reports from the consultations, please visit the documents libary page.
Draft proposal process
Pre-draft proposal, version 9 February 2022: European Partnership for One Health/AMR Antimicrobial Resistance (AMR)
- 2021-2023: Identification of research and innovation objectives and definition of Partnership objectives and Roadmap of joint actions.
- 2022-2023: Collection of Members States commitments
- 2024: SRIA and proposal submission to the European Commission
- 2025: Launch of first call and start of activities
To stay updated about the progress of the OH AMR Partnership please subscribe to the JPIAMR newsletter.
DESIGN OH AMR
The EU Horizon Europe has granted a coordination and support action (CSA) to work on the design of the candidate OH AMR partnership and act as a facilitator for its development. This CSA, DESIGN One Health AntiMicrobial Resistance (DESIGN OH AMR), is also expected to prepare the Strategic Research & Innovation Agenda, including the intervention logic underpinning it.
Read more about the CSA DESIGN OH AMR.
Further information and contact
Contact JPIAMR: email@example.com
Contact Commission services: RTD-COMBATTING-DISEASES@ec.europa.eu